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Highlights 
 A high rate of radiologically confirmed symptomatic fractures (48%) was identified. 
 Non-vertebral fractures occurred predominantly at femur and tibia after minor falls. 
 DMD bone monitoring is currently inconsistent despite consensus guidance. 
Abstract  
There are limited reports of radiologically confirmed fractures and bone health monitoring in 
with Duchenne Muscular Dystrophy. We performed a retrospective study of 91 boys, with a 
median age of 11.0 years, who are currently managed in Scotland with the aim to assess the 
frequency of radiologically confirmed fractures and report on bone health monitoring in 
relation to International Care Consensus Guidance. Of these boys, 59 (65%) were receiving 
glucocorticoid (GC) therapy and 23 (25%) had received previous treatment. Of those 
currently on GC, 37 (63%) had an assessment of bone mineral density and none had routine 
imaging for vertebral fractures during the study period. Of the 91 boys, 44 (48%) had 
sustained at least one symptomatic radiographically confirmed fracture. The probability of 
sustaining a first symptomatic fracture was 50% by 12.8 years old (95%CI: 12.1, 13.6). The 
most common sites for non-vertebral fracture were the femur and tibia. In this review of boys 
with DMD, almost half had sustained at least one radiologically confirmed symptomatic 
fracture. There is a need for standardized bone health monitoring in DMD that includes 
routine imaging of the spine to identify vertebral fractures, given the persistence of insult to 
the skeleton in these boys. 
Introduction  
Duchenne Muscular Dystrophy is an X-linked recessive disorder occurring in 1 in 4000 live 
male births 1. DMD is a life-limiting disorder associated with progressive muscle 
inflammation, degeneration, fatty infiltration and fibrosis leading to progressive motor 
disability. Most affected boys will be wheel chair dependent by the age of 12 years. 
Glucocorticoid (GC) therapy is the only disease-modifying option, which has been shown to 
improve short-term muscle function and strength 2 but other benefits including preservation 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 3 
of upper limb function, reduction in risk of scoliosis and preservation of cardiac function are 
reported with prolonged use 3-5. However, prolonged use of GC is associated with 
abnormalities of growth and skeletal development 6. Due to the high fracture frequency, 
several international workshops have developed consensus on monitoring and management 
of bone health in DMD, including the need for vitamin D supplementation, regular monitoring 
of vitamin D levels and evaluation of bone mass with dual energy absorptiometry (DXA) 7-9. 
Previous studies have shown that fractures may lead to premature loss of ambulation and 
may be associated with severe and life threatening complications like fat embolism 
syndrome 10. 
Whilst it is recognized that fractures are common in these boys, it is difficult to be 
certain of the prevalence of fracture from published studies. Based on patient recall or case 
note review 11-17, fractures have been reported in over 40% of boys and young men. 
However, it is not clear from these reports if complete case ascertainment was achieved. In 
addition, most published studies are from a single site. 
In Scotland, the care of boys with DMD is delivered locally in seven paediatric 
centres using nationally agreed standards within the framework of a national managed 
clinical network. All radiological imaging is available for sharing on a single national platform. 
The aim of this study was to utilize these opportunities and assess the occurrence of 
radiologically confirmed symptomatic fractures in boys and adolescents with DMD. In 
addition, a secondary aim of the study was to report on bone health monitoring in boys 
managed in Scotland. 
Methods 
A retrospective review of bone health of 91 boys with DMD currently managed in the 
7 centres supported by the Scottish Muscle Network (SMN, www.smn.scot.nhs.uk) was 
performed as part of a service evaluation in December 2015. Cases were identified from a 
registry held by the SMN and cross-checked with the lead neuromuscular clinicians in the 7 
centres in Scotland. Information on all cases from diagnosis to last clinic visit, closest to 
December 2015 were collected. The diagnosis of DMD was confirmed by DNA diagnostic 
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technique and/or confirmatory muscle biopsy.  
Fractures were identified from the national radiological archive report (Picture 
Archiving and Communication System (PACS), GE Systems, Milwalkee, Wis) and classified 
into vertebral fracture (VF) and non-VF. X-rays were performed as clinically indicated due to 
symptoms of limb pain, back pain, documented injuries or swelling. Routine screening lateral 
thoracolumbar spine x-rays was not adopted as part of clinical care during the period of 
study. All X-rays were reported by a consultant radiologist at the local centre. Detailed 
characteristics of fractures were collected from case notes including mechanism of fracture 
and clinical characteristics at the time of fracture including age, GC regimen and duration, 
mobility status, vitamin D levels, dual energy x-ray absorptiometry (DXA). Non-ambulant 
status was defined by a continuous use of a wheelchair. DXA was performed for total body 
(TB) and lumbar spine (LS) bone mineral content (BMC) adjusted for bone area (BAr) as 
previously described, using Lunar Prodigy (GE Medical Systems, Waukesha, Wis., USA) 18.  
Anthropometric measurements (height, body mass index) were converted into standard 
deviation score (SDS) using the 1990 UK growth reference data 19, 20. Ambulant boys were 
measured by standing height whereas non-ambulant boys who had growth monitoring were 
measured by arm span.  
 
Statistics 
Statistical analysis was conducted using IBM SPSS Statistics Software Version 22 
(SPSS Inc, Chicago). Results are reported as median (25th and 75th centile). The effect of 
age and the duration of GC therapy on the probability of fractures was determined by 
Kaplan–Meier analysis in median (95% confidence interval). For the analysis of time to first 
fracture (VF and non-VF) against age and GC duration, censored cases were included. In 
addition, boys who discontinued GC were also included. A level of p<0.05 was used to 
denote statistical significance. 
 
Results 
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Population Characteristics 
Details of all 91 boys at last clinic visit are summarised in Table 1. The median age of 
the cohort was 11.3 years (7.8, 15.0). Of the 91, 46 (51%) were non-ambulant. Median 
height SDS at last clinic visit was available in 76 boys and was -1.4 (-2.7, -0.8). Of the 76, 19 
(25%) had a height SDS < -2.0. Median BMI SDS was +1.6 (0.7, +2.2) with 13 (30%) having 
a BMI SDS > +2.0.  
 
Glucocorticoid therapy 
Of the 91, 59 (65%) were on GC therapy at last clinic visit and 23 (25%) were 
previously treated with GC. Median length of GC in the boys who were previously treated 
was 4.2 years (2.8, 6.6). Of the 23 who were previously treated with GC, 17 discontinued at 
the time of loss of ambulation at a median age of 10.2 years (9.0, 11.5). Five discontinued 
after loss of ambulation due to excessive weight gain and 1 discontinued due to severe 
behavioural issues whilst still ambulant at 9.6 years of age.   There were four different GC 
regimens used [Table 1]. Of the 59 on GC, 23 (40%) were treated with daily Deflazacort and 
only one boy was managed on pulsed Deflazacort. GC regimen was unknown for six who 
were enrolled in a randomized trial with the aim to evaluate the optimal GC regimen in DMD. 
All six were however treated with GC. Of the 32 who were not currently on GC, 9 were 
younger GC naïve boys (≤ 5 years).  Median hydrocortisone equivalent was highest in daily 
Deflazacort, followed by daily Prednisolone and pulsed Prednisolone regimen at a median 
dose of 94.0 mg/m2/day (45.0, 138.0), 69.5 mg/m2/day (64.8, 75.8), 31.0 mg/m2/day (13.5, 
37.0), respectively.   
 
Bone health monitoring 
 Of the 91, 46 (51%) had plasma 25 hydroxy-vitamin D levels measured in the last 12 
months. Median vitamin D level was 49 nmol/L (23, 143). Of the 91, 63 (69%) had at least 
one DXA assessment. Of the 28 who have never had any DXA assessment, 8 (29%) were 
GC naïve boys ≤ 5 years. Of the 59 currently on GC, 37 (63%) had a DXA assessment in the 
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last 2 years.  
 
Vitamin D therapy 
 Of the 91, 69 (76%) were on vitamin D supplementation. Of the 59 currently on GC, 
48 (81%) were on vitamin D supplementation. Median vitamin D dose was 800 IU daily (400, 
1400).  
 
Bisphosphonate therapy  
Of the 91, 10 (11%) were receiving bisphosphonate therapy. Of the 10, 8 (80%) were 
receiving intravenous bisphosphonate therapy, of whom six were on zoledronate, and two on 
pamidronate. The indications for treatment were symptomatic VFs in 7 boys and multiple 
long bone fractures in another boy. The remaining two boys (20%) were receiving oral 
risedronate. One was commenced after a long bone fracture, and the other was started as 
prophylaxis, however, subsequently developed femoral fracture on treatment. Two other 
boys were previously treated with bisphosphonate.  Of these, one boy received a single 
dose of pamidronate for back pain with low LS bone mineral density SDS -2.5 without 
evidence of VF on X-ray. The other boy completed two years of 4 monthly pamidronate for 
symptomatic VF. 
 
Testosterone therapy 
Of the 91, 29 (32%) were 14 years or older and of this group, pubertal assessment 
was only documented in 14 (48%), all following referral to paediatric endocrinologist as a 
result of parental or clinician concern about delayed puberty.  Of the 29, 11 (79%) were 
prepubertal with testes volume of less than 4 ml. Of these 11 boys, five were on 
intramuscular testosterone and two on oral testosterone for pubertal induction. None had 
received growth hormone therapy.  
 
Fracture occurrence 
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Of the 91, 44 (48%) sustained a total of 51 fractures. Of the 91, 36 (40%) had non-
VFs, 7 had symptomatic VFs (8%) and 1 had both non-VFs and symptomatic VFs.   Of the 
44, 5 (11%) sustained multiple fractures. The number of fractures sustained per individual 
ranged from 1 to 4. There were 43 non-VF episodes and these occurred predominantly in 
the lower limb in 31 (72%) [Figure 1] with the most common site being the femur in 14 (33%) 
followed by tibia in 12 (30%).  Of the 43 non-VF episodes, 36 (84%) were fragility fractures 21 
with 26 (61%) occurring after a fall from a standing position and 10 (23%) occurring in non-
ambulant boys following a fall from a sitting position. In 6 (14%), non-VFs occurred following 
a history of minor trauma and in 1 boy mechanism of injury was not documented. All the 8 
boys with symptomatic VFs presented with multiple painful VFs. The location of fractures 
included multiple thoracic and lumbar in 6, multiple lumbar in 1 and multiple thoracic in 1. A 
boy sustained three long bone fractures before the diagnosis of symptomatic VF. The first 
fracture was fracture of the tibia aged 2.1 years due to a fall from standing, prior to treatment 
with GC.  
Of the 36 boys who sustained non-VFs, 20 (56%) were ambulant prior to the fracture 
and 7 (35%) never regained ambulation following the fracture. 6 out of the 8 (75%) boys 
were ambulant at the time that symptomatic VFs were diagnosed. None of the boys lost 
ambulation following diagnosis of symptomatic VF.   
 
Age and fracture 
The probability of developing a first symptomatic fracture (non-VF or symptomatic 
VF) was 50% by 12.8 years old (95%CI 12.1 to 13.6) [Figure 2a]. The probability of 
developing non-VF was 50% by 13.6 years old (95% CI 12.3 to 14.8). Non-VFs occurred 
over a wide age range of 2.0 to 17.4 years. The probability of developing symptomatic VF 
was 50% at 11.4 years old (95% CI 10.0 to 12.4).  Symptomatic VFs occurred over an age 
range of 5.6 to 15.9 years.  
  
GC duration and fracture 
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The probability of developing a first symptomatic fracture (non-VF or symptomatic 
VF) was 50% after 6.5 years of GC exposure (95% CI 5.4 to 7.5) [Fig. 2b]. The probability of 
developing non-VF was 50% after 8.2 years of GC exposure (95% CI 6.2 to 10.2). Seven 
non-VFs occurred in 26 ambulant GC-naïve boys with a median age at fracture of 3.5 years 
(2.0, 10.1). In contrast, symptomatic VFs only occurred in the GC-treated cohort. There was 
a latency of 2.3 years before the development of the first symptomatic VF. The probability of 
developing symptomatic VF was 50% at 3.7 years of GC exposure (95% CI 2.8 to 5.3).   
. 
Vitamin D, DXA and fracture 
Of the 51 fracture events, 33 (65%) had 25 hydroxy-vitamin D measured at the time 
of fracture. Median 25 hydroxy-vitamin D concentration at time of fracture was 49 nmol/L 
(24, 69). Of the 33, 3 (9%) had measurements <25 nmol/L. Of the 47 who did not sustain 
any fractures, median 25 hydroxy-vitamin D at last visit was 49 nmol/L (20,125). 
Of the 51 fracture events, DXA TB BMC SDS and LS BMC SDS within six months of 
fracture were available in 18 (35%) and 17 (33%), respectively. Of the 13 with non-VFs who 
had a DXA within 6 months of the fracture, only one had TB BMC SDS < -2.0. Of the 5 with 
VFs who had a DXA within 6 months of the fracture, similarly only one had TB BMC SDS 
and LS BMC SDS < -2. 
Discussion 
This study of a contemporary group of boys with DMD managed in Scotland showed 
that almost half of the group had sustained at least one fracture and almost 9% of boys had 
presented with severe painful VFs. The mechanisms of injury suggest that 84% of non-VFs 
in our DMD boys were classified as fragility fractures, occurring following a fall from standing 
height or less21. Our study also showed that bone monitoring in Scotland according to 
current international consensus remains inconsistent, although it is unclear if this is an issue 
in other regions 7-9. Only half of the cohort had vitamin D levels measured in the previous 
twelve months and only approximately 60% of GC treated boys had a DXA scan in the 
previous two years.  
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When compared to the prevalence of fracture of 9% reported in a large cohort of 
healthy children in the United Kingdom, the prevalence of fracture in DMD in the current 
study (48%) is clearly much higher 22. In healthy children, upper limb long bone fractures at 
radius and ulna are the most common sites. In contrast, the two most common sites of 
fractures in the current cohort are femur and tibia 22. A previous study has reported that 
lower limb fractures are the most common non-VFs but to the best of our knowledge detailed 
information on fracture sites in DMD have not been reported 23. Compared to published 
studies of fractures in DMD, the frequency of non-VFs of 40% in the current study appears to 
be higher than the reported frequency of 23-30%, although a recent study has also reported 
similar frequencies of non-VF 24. We believe that the frequency of non-VF in the current 
study is robust given that we included cases that were radiologically confirmed.  
The prevalence of VFs of almost 9% in the current study is much lower than the 
reported 18-76% in published literature in DMD 15-17, 23-27. Several factors could explain the 
differences in fracture occurrence including number of cases, GC regimen and dose, 
duration of treatment/follow-up and method of VF identification. Ten percent of the study 
cohort was also GC naïve. In recent studies, VF was detected in 53-76% in groups of boys 
on daily GC for at least three years when routine spine imaging was incorporated as part of 
bone health monitoring 24, 25. During the study period, none of the Scottish centres included 
routine spine imaging for VF. We believe that the frequency of almost 9% of VF presenting 
with significant pain in our cohort represents a gross underestimation in these boys. It is now 
well recognized that VF in children with chronic conditions are often asymptomatic 26-28. 
Since 2016, we have revised the bone monitoring guidance of the Scottish Muscle Network, 
to incorporate routine thoracolumbar spine x-rays (at least every 2 years) to detect VF 24. 
The frequency of VF up to 16% is reported at diagnosis in other groups of children 
with treated with GC where systematic screening with spine x-rays was conducted 28-30. In 
childhood leukaemia, where intermittent GC is used, almost a quarter developed VF over a 
period of four years when a routine screening programme with spine x-rays was in place30. 
Vertebral reshaping is possible in some children with leukaemia or other children with 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 10 
chronic conditions who develop VF during shorter duration of GC therapy 6, 31,33, 34. On the 
other hand, results from a retrospective study suggest that there is absent vertebral 
reshaping after diagnosis of VF in DMD which may be due to the prolonged period of GC 
therapy and irreversibility of the skeletal insult24.  In our current review, we identified that 
delayed puberty is very common and present in almost 80% of older adolescents who have 
had clinical assessment of puberty following referral to paediatric endocrinology35. However, 
puberty was only documented in half the cohort of boys age 14 years and older. The 
prevalence of delayed puberty in these GC treated boys is therefore currently still unknown. 
Testosterone leads to increased bone mass by increasing periosteal expansion 36-38 and 
pubertal delay will no doubt contribute in part to poor bone development in these 
adolescents. Emerging evidence suggests that these boys have persistent hypogonadism, 
and may therefore have long-term consequences to the skeleton even in adulthood39. There 
are limited studies on the effects of testosterone on skeletal development and growth in boys 
with DMD but this deserves greater attention 39.  The importance of assessment and 
management of delayed puberty in these boys is addressed in our updated bone monitoring 
guidance, which recommends routine pubertal assessment from the age of 13 years, ideally 
by a paediatric endocrinologist. Management of puberty with testosterone from the age of 14 
years building up to adult doses over a period of 2 to 3 years is currently our clinical practice. 
It is worth noting that the median age of loss of ambulation in our national cohort of 
boys with DMD appears to be younger than those reported in some recent literature 40. In 
contrast to a recent report 16, we did not find increased fracture incidence around the time of 
loss of ambulation, even though the age at loss of ambulation in our national cohort appears 
to be similar to that study and also other reports 41.  Some of the other published studies 
reporting a much later age of loss of ambulation are either from relatively small cohorts or 
did not include censored cases, thereby creating a bias of excluding those cases with a 
more severe phenotype or less responsive to GC 23,42,43. The number of subjects in this 
study poses limitation in applying multivariable analysis to explore the influence of covariates 
on fracture risk. For example, the influence of different GC regimens, bisphosphonates, 
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testosterone therapies, pubertal status, vitamin D levels and bone mineral density will 
require exploration in a larger cohort. The complex interplay between underlying muscle 
weakness and GC therapy, together with other factors that may impact on bone health and 
therefore fracture risk in DMD needs to be teased out in well-designed research studies. 
Routine imaging with lateral thoracolumbar spine x-rays should be incorporated into such 
studies, and indeed in clinical monitoring of these boys44.  
 
Conclusion 
In summary, in one of the largest studies to date with complete ascertainment of 
boys with DMD, the current study reports a very high rate of radiologically confirmed 
fractures. The frequency of VF in our study is however likely to be a gross underestimation 
of the real frequency in this population. Bone monitoring in this national cohort is inconsistent 
and should now include routine imaging of the spine with lateral thoracolumbar spine x-rays. 
Routine pubertal assessment in these boys should be given attention in the neuromuscular 
clinics with timely referral to paediatric endocrinology for management of puberty. Multi-
centre prospective studies are required to clearly understand the determinants of 
asymptomatic as well as symptomatic fractures in this at-risk group. 
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Legend to figures 
Figure 1:  Anatomical location of non-VFs in boys with DMD.  
Of the 91 boys, 37 developed non-VF (including 1 boy with non-VF and VF). 
The 37 boys sustained a total of 43 non-VFs.   
[VF: vertebral fracture; DMD: Duchenne muscular dystrophy]. 
Figure 2:  Probability of fracture in boys with DMD against age and duration of GC 
exposure 
Horizontal dotted line refers to 50% probability of fracture (Fig a, and b). 
Vertical continuous line refers to mean age of loss of ambulation of boys with 
DMD in our cohort (Fig a). Vertical dotted lines refers to ± 1 standard 
deviation from the mean of age of loss of ambulation (Fig a). 
[DMD: Duchenne muscular dystrophy; VF: vertebral fracture; GC: 
glucocorticoid] 
(a) Probability of first symptomatic fracture in DMD over time (against age) 
using Kaplan-Meier analysis 
The probability of developing first symptomatic fracture (symptomatic VF 
and non-VF) was 50% by 12.8 years of age. (Censored cases are shown 
as the crosses on Kaplan-Meier graph). Cases with previous GC 
treatment were also included. 
(b) Probability of first symptomatic fracture in DMD in relation to duration of 
GC exposure using Kaplan-Meier analysis 
The probability of developing first symptomatic fracture (symptomatic VF 
and non-VF) was 50% after 6.5 years of GC exposure. (Censored cases 
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are shown as the crosses on Kaplan-Meier graph). Cases with previous 
GC treatment were also included. 
  
n (%) 
 
 
Median (25
th
, 75
th
 
centile) 
 
Age (years) 
 
 
91/91(100%) 
 
11.0 (7.8, 15.0) 
Height SDS 
 
76/91 (84%) -1.4 (-2.7, -0.8) 
BMI SDS 
 
76/91 (84%) +1.5 (0.7, 2.2) 
Non-ambulant cohort 
 
46/91 (51%)  
Age at loss of ambulation (years) 
 
46/46 (100%) 10.2 (8.8,11.7) 
Length of non-ambulation state (years) 
 
46/46 (100%) 2.9 (1.5, 6.0) 
Current GC treatment 
 
59/91 (65%)  
Previous GC treatment 
 
GC naïve 
23/91 (25%) 
 
9/91 (10%) 
 
 
Age at start of GC (years) 
 
 
82/82 (100%) 
 
5.5 (4.4, 6.6) 
Duration of GC therapy (years) 
 
82/82 (100%) 5.2 (2.4, 8.0) 
Hydrocortisone equivalent dose (mg/m
2
/day) 
-Daily deflazacort 
-Daily prednisolone 
-Pulsed prednisolone 
-Pulsed deflazacort 
-Unknown GC regimen (Clinical Trial) 
 
23/59 (40%) 
16/59 (27%) 
13/59 (22%) 
1/59 (2%) 
6/59 (10%) 
 
94.0 (45,138) 
69.5 (64.8, 75.8) 
31.0 (13.5,37.0) 
66.0 
 
 
Table 1: Clinical characteristics of boys with DMD in Scotland at last clinic visit 
SDS: standard deviation score; BMI: body mass index; GC: glucocorticoid; mg: milligram; m
2 
: meter 
square; DMD: Duchenne muscular dystrophy 
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Figure 2(b) 
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